Menin inhibitors are an emerging class of biomarker-directed therapy for KMT2A-rearranged acute myeloid leukemia (AML), and there is an abundance of safety and efficacy data being released to guide their use in clinical practice. Join this Clinical Mic Drop as an expert in AML reviews pivotal clinical trial data from the latest publications and ASH 2024 conference presentations concerning menin inhibitors for the treatment of KMT2A-rearranged AML.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/latest-clinical-evidence-menin-inhibitors-kmt2a-rearranged-acute-myeloid
- Start Date: 2025-01-15 06:00:00
- End Date: 2025-01-15 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.25 hours
AMA PRA Category 1 Credit™️: 0.25 hours
Nursing: 0.25 hours
Pharmacy: 0.25 hours - Commercial Support: Source: Syndax Pharmaceuticals - Amount: 24875.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest